9 research outputs found
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015:a systematic review and modelling study
Background:
We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015.
Methods:
We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity.
Findings:
We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population.
Interpretation:
Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group
Population-based otoscopic and audiometric assessment of a birth cohort recruited for a pneumococcal vaccine trial 15–18 years earlier: a protocol
Introduction A cohort of 12 000 children in the Philippines who had enrolled in a 2000–2004 (current ages 16 to 20 years) Phase 3 11-valent pneumococcal conjugate vaccine for the prevention of radiographically confirmed pneumonia are now being asked to participate in a separate study (expected completion date September 2021) to assess the cohort’s current long-term audiometric and otologic status. This new study would allow assessments of the utility of the pneumococcal vaccine in conferring its protective effects on the long-term sequelae of otitis media (OM), if any. Lack of trained local healthcare providers in otolaryngology/audiology and testing equipment in Bohol, Philippines, necessitates the development of a distinct methodology that would lead to meaningful data analysis.Methods and analysis Reliable data collection and transfer are achieved by a US otolaryngologist/audiologist team training local nurses on all procedures in a didactic and hands-on process. An assortment of portable otolaryngologic and audiologic equipment suitable for field testing has been acquired, including an operating otoscope (Welch-Allyn), a video-otoscope (JedMed), a tympanometer with distortion product otoacoustic emission measurements (Path Sentiero) and a screening audiometer (HearScreen). Data will then be uploaded to a Research Electronic Data Capture database in the USA.Tympanometric and audiologic data will be codified through separate conventional algorithms. A team of paediatric otolaryngology advanced practice providers (APPs) have been trained and validated in interpreting video otoscopy. The protocol for classification of diagnostic outcome variables based on video otoscopy and tympanometry has been developed and is being used by APPs to evaluate all otoscopy data.Ethics and dissemination The study was approved by the Research Institute of Tropical Medicine, Alabang, Manila, Philippines, and the institutional review board and the Colorado Multiple Institutional Review Board of the University of Colorado School of Medicine, Aurora, Colorado, USA.Research results will be made available to children and their caregivers with abnormal audiologic outcomes, the funders and other researchers.Trial registration number ISRCTN 62323832; Post-results
Pathogen chip for respiratory tract infections.
Determining the viral etiology of respiratory tract infections (RTI) has been limited for the most part to specific primer PCR-based methods due to their increased sensitivity and specificity compared to other methods, such as tissue culture. However, specific primer approaches have limited the ability to fully understand the diversity of infecting pathogens. A pathogen chip system (PathChip), developed at the Genome Institute of Singapore (GIS), using a random-tagged PCR coupled to a chip with over 170,000 probes, has the potential to recognize all known human viral pathogens. We tested 290 nasal wash specimens from Filipino children <2 years of age with respiratory tract infections using culture and 3 PCR methods-EraGen, Luminex, and the GIS PathChip. The PathChip had good diagnostic accuracy, ranging from 85.9% (95% confidence interval [CI], 81.3 to 89.7%) for rhinovirus/enteroviruses to 98.6% (95% CI, 96.5 to 99.6%) for PIV 2, compared to the other methods and additionally identified a number of viruses not detected by these methods
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
BACKGROUND: We have previously estimated that respiratory
syncytial virus (RSV) was associated with 22% of all episodes of
(severe) acute lower respiratory infection (ALRI) resulting in
55 000 to 199 000 deaths in children younger than 5 years in
2005. In the past 5 years, major research activity on RSV has
yielded substantial new data from developing countries. With a
considerably expanded dataset from a large international
collaboration, we aimed to estimate the global incidence,
hospital admission rate, and mortality from RSV-ALRI episodes in
young children in 2015. METHODS: We estimated the incidence and
hospital admission rate of RSV-associated ALRI (RSV-ALRI) in
children younger than 5 years stratified by age and World Bank
income regions from a systematic review of studies published
between Jan 1, 1995, and Dec 31, 2016, and unpublished data from
76 high quality population-based studies. We estimated the
RSV-ALRI incidence for 132 developing countries using a risk
factor-based model and 2015 population estimates. We estimated
the in-hospital RSV-ALRI mortality by combining in-hospital case
fatality ratios with hospital admission estimates from
hospital-based (published and unpublished) studies. We also
estimated overall RSV-ALRI mortality by identifying studies
reporting monthly data for ALRI mortality in the community and
RSV activity. FINDINGS: We estimated that globally in 2015, 33.1
million (uncertainty range [UR] 21.6-50.3) episodes of RSV-ALRI,
resulted in about 3.2 million (2.7-3.8) hospital admissions, and
59 600 (48 000-74 500) in-hospital deaths in children younger
than 5 years. In children younger than 6 months, 1.4 million (UR
1.2-1.7) hospital admissions, and 27 300 (UR 20 700-36 200)
in-hospital deaths were due to RSV-ALRI. We also estimated that
the overall RSV-ALRI mortality could be as high as 118 200 (UR
94 600-149 400). Incidence and mortality varied substantially
from year to year in any given population. INTERPRETATION:
Globally, RSV is a common cause of childhood ALRI and a major
cause of hospital admissions in young children, resulting in a
substantial burden on health-care services. About 45% of
hospital admissions and in-hospital deaths due to RSV-ALRI occur
in children younger than 6 months. An effective maternal RSV
vaccine or monoclonal antibody could have a substantial effect
on disease burden in this age group. FUNDING: The Bill &
Melinda Gates Foundation